An prospective, exploratory, randomized, controlled clinical Study of Apatinib combined radiotherapy Compared with zoledronic acid combined radiotherapy Treatment in Patients With bone metastases of Malignant tumor

Next Previous
Trial Profile

An prospective, exploratory, randomized, controlled clinical Study of Apatinib combined radiotherapy Compared with zoledronic acid combined radiotherapy Treatment in Patients With bone metastases of Malignant tumor

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Rivoceranib (Primary) ; Zoledronic acid
  • Indications Adenocarcinoma; Bone metastases; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top